Phospho-ANAPC1 (S355) Antibody

What is ANAPC1 and why is the S355 phosphorylation site significant?

ANAPC1 (Anaphase Promoting Complex Subunit 1, also known as APC1) is a core component of the anaphase-promoting complex/cyclosome (APC/C), which functions as a cell cycle-regulated E3 ubiquitin ligase. This complex plays a crucial role in controlling progression through mitosis and the G1 phase of the cell cycle by mediating ubiquitination and subsequent degradation of target proteins .

The S355 phosphorylation site on ANAPC1 is particularly significant as it represents a regulatory post-translational modification that influences APC/C activity during cell division. Research indicates that phosphorylation at this site increases during mitosis, suggesting it may serve as a control mechanism for the complex's activity . The phosphorylation state of ANAPC1 at S355 can therefore serve as a biomarker for specific cell cycle phases and potentially for cellular dysregulation in disease states.

What are the structural characteristics of the ANAPC1 protein?

ANAPC1 is a large protein with the following characteristics:

The protein contains multiple domains that facilitate interactions with other APC/C subunits and contributes to the formation of 'Lys-11'-linked polyubiquitin chains and, to a lesser extent, 'Lys-48'- and 'Lys-63'-linked chains .

How does ANAPC1 contribute to cell cycle regulation?

ANAPC1 serves as a structural scaffold for the APC/C complex, which acts as the primary E3 ubiquitin ligase regulating the metaphase-to-anaphase transition and mitotic exit. The complex functions by:

• Targeting cell cycle regulatory proteins for degradation by the proteasome, thereby allowing progression through the cell cycle

• Mediating the formation of primarily 'Lys-11'-linked polyubiquitin chains on substrate proteins

• Catalyzing the assembly of branched 'Lys-11'-/'Lys-48'-linked ubiquitin chains on target proteins

• Responding to spindle checkpoint proteins that regulate its activity

The phosphorylation of ANAPC1 at S355 appears to modulate its activity, with phosphorylated ANAPC1 being more abundant in cells arrested in mitosis compared to asynchronous cells .

Experimental Applications and Methodologies

Based on published methodologies and manufacturer recommendations:

• Sample Preparation:

  • Use whole cell lysates (approximately 30 μg per lane)

  • For enhanced phospho-signal, compare asynchronous cells with cells arrested in mitosis (e.g., using nocodazole treatment)

• Gel Electrophoresis:

  • Use 4-8% SDS-PAGE for optimal separation of this high molecular weight protein (~215 kDa)

• Transfer and Blocking:

  • Transfer to nitrocellulose membrane

  • Block with appropriate blocking buffer (typically 5% BSA in TBST)

• Primary Antibody Incubation:

  • Dilute the Phospho-ANAPC1 (S355) antibody to 1:500-1:1000

  • Incubate overnight at 4°C

• Secondary Antibody and Detection:

  • Use anti-rabbit secondary antibody (e.g., 1:10,000 dilution of IRDye800 conjugated Gt-a-Rabbit IgG)

  • Incubate for 45 minutes at room temperature

  • Visualization can be performed using fluorescent imaging systems or standard chemiluminescence

This protocol has been successfully employed to detect the ~215 kDa band corresponding to phosphorylated human APC1, with increased signal intensity in mitotically arrested cells .

How should researchers prepare tissue samples for immunohistochemistry with this antibody?

For optimal IHC results with Phospho-ANAPC1 (S355) antibody:

• Tissue Fixation and Processing:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissue sections

  • Standard 5 μm sections are recommended

• Antigen Retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 8.0)

  • Boil for 15-20 minutes followed by cooling to room temperature

• Blocking and Antibody Application:

  • Block with appropriate serum (e.g., 10% normal goat serum)

  • Apply Phospho-ANAPC1 (S355) antibody at 1:100-1:300 dilution

  • Incubate overnight at 4°C or 1-2 hours at room temperature

• Detection System:

  • Use biotin-streptavidin-HRP system or polymer-based detection systems

  • Develop with DAB (3,3'-diaminobenzidine) or other appropriate chromogen

  • Counterstain with hematoxylin

IHC studies have demonstrated moderate positive cytoplasmic and occasional nuclear staining in various tissue types, including pancreatic carcinoma cells .

How should researchers interpret Western blot results showing phosphorylated ANAPC1?

When interpreting Western blot results:

• Expected Band Size:

  • Look for a specific band at approximately 215 kDa, which corresponds to phosphorylated human APC1

• Signal Intensity Patterns:

  • Expect higher phosphorylation levels in mitotically arrested cells compared to asynchronous populations

  • Published data shows that while some phosphorylated APC1 is present in untreated cells, the amount of phosphorylated protein increases in cell preparations arrested in mitosis

• Controls to Include:

  • Positive control: Lysates from nocodazole-treated cells (mitotically arrested)

  • Negative control: Consider using a phosphatase-treated sample

  • Loading control: A housekeeping protein to normalize expression levels

• Potential Variations:

  • The exact molecular weight may vary slightly depending on the gel percentage and running conditions

  • Post-translational modifications other than S355 phosphorylation might affect mobility

What controls are essential when studying ANAPC1 phosphorylation dynamics?

To ensure reliable and interpretable results when investigating ANAPC1 phosphorylation:

• Experimental Controls:

  • Phosphatase Treatment: Treat duplicate samples with lambda phosphatase to confirm phospho-specificity

  • Cell Cycle Synchronization: Compare asynchronous cells with synchronized populations at different cell cycle stages

  • Blocking Peptide: Use the specific phospho-peptide immunogen to confirm antibody specificity

• Biological Controls:

  • Cell Line Panel: Test multiple cell lines with known differences in cell cycle regulation

  • Mitotic Arrest: Include nocodazole-treated samples as positive controls for increased phosphorylation

  • Kinase Inhibition: Use specific inhibitors of cell cycle-regulated kinases to examine phosphorylation dependency

• Technical Controls:

  • Antibody Concentration Gradient: Test multiple dilutions to ensure you're working in the linear range

  • Total ANAPC1 Detection: Use a non-phospho-specific ANAPC1 antibody in parallel to assess total protein levels

These controls will help distinguish between specific phosphorylation changes and experimental artifacts.

How does phosphorylation at S355 correlate with other ANAPC1 modifications?

Current research indicates:

• Multiple Phosphorylation Sites:

  • ANAPC1 contains several phosphorylation sites, including S355 and S688

  • These modifications may work cooperatively or independently to regulate APC/C function

• Temporal Dynamics:

  • S355 phosphorylation increases during mitosis, suggesting cell cycle-dependent regulation

  • The temporal relationship between different phosphorylation events on ANAPC1 remains an area of active investigation

• Functional Consequences:

  • S355 phosphorylation may affect protein-protein interactions within the APC/C complex

  • It might also influence substrate recognition or catalytic activity

Further studies using both phospho-specific antibodies and mass spectrometry approaches are needed to fully characterize the interplay between different post-translational modifications on ANAPC1.

How can phospho-specific ANAPC1 antibodies be used to study cell cycle dysregulation in cancer?

Phospho-ANAPC1 (S355) antibodies offer valuable tools for cancer research:

• Biomarker Development:

  • Assess phospho-ANAPC1 levels in tumor tissues compared to normal counterparts

  • Correlate phosphorylation status with clinical outcomes and treatment responses

  • Studies have already shown utility in pancreatic carcinoma tissue analysis

• Cell Cycle Checkpoint Analysis:

  • Investigate whether altered ANAPC1 phosphorylation contributes to checkpoint bypass in cancer cells

  • Compare phosphorylation dynamics in response to anti-mitotic drugs between sensitive and resistant cell lines

• Mechanistic Studies:

  • Combine with genetic approaches (siRNA, CRISPR) targeting kinases or phosphatases to identify regulators

  • Assess how oncogenic signaling pathways affect ANAPC1 phosphorylation

  • Determine if phosphorylation status affects APC/C substrate specificity in cancer contexts

• Therapeutic Target Evaluation:

  • Monitor changes in ANAPC1 phosphorylation in response to cell cycle-targeting drugs

  • Identify correlations between phosphorylation status and sensitivity to specific therapies

Research has indicated ANAPC1 involvement in myeloma, making phospho-specific detection particularly relevant in hematological malignancy studies.

What are the technical considerations for multiplex analysis of cell cycle regulators including phospho-ANAPC1?

When designing multiplex experiments:

• Antibody Compatibility:

  • Ensure primary antibodies are from different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies (common for phospho-specifics), consider sequential staining with complete stripping between rounds

• Fluorescent Multiplex Immunohistochemistry:

  • Use tyramide signal amplification (TSA) systems for sequential detection

  • Carefully select fluorophores with minimal spectral overlap

  • Include single-stain controls to assess bleed-through

• Multiplex Western Blotting:

  • Use antibodies that target proteins of significantly different molecular weights

  • Alternatively, strip and reprobe membranes for phospho-ANAPC1 (215 kDa) and other cell cycle regulators

  • Consider fluorescent secondary antibodies with different emission spectra for simultaneous detection

• Flow Cytometry Applications:

  • Combine phospho-ANAPC1 staining with DNA content analysis

  • Include markers for specific cell cycle phases (e.g., pH3 for mitosis)

  • Perform careful compensation when using multiple fluorochromes

• Data Analysis:

  • Use appropriate software for colocalization or correlation analysis

  • Consider machine learning approaches for pattern recognition in complex datasets

  • Always include appropriate single-stain controls for accurate spectral unmixing

How does ANAPC1 phosphorylation relate to its role in the anaphase-promoting complex?

The relationship between ANAPC1 phosphorylation and APC/C function involves several mechanisms:

Understanding these relationships requires integrated approaches combining phospho-specific antibodies with functional assays of APC/C activity.

What are the most common issues encountered when using Phospho-ANAPC1 (S355) antibodies and how can they be resolved?

Researchers frequently encounter these challenges:

• Weak or No Signal in Western Blotting:

  • Problem: Insufficient phosphorylated protein in sample

  • Solution: Use mitotically arrested cells (e.g., nocodazole treatment) to increase phosphorylation

  • Problem: Inefficient protein transfer

  • Solution: Use optimized transfer conditions for high molecular weight proteins (215 kDa), such as longer transfer times or lower percentage gels (4-8%)

• High Background in Immunohistochemistry:

  • Problem: Non-specific binding

  • Solution: Optimize blocking conditions (duration, buffer composition)

  • Problem: Excessive antibody concentration

  • Solution: Titrate antibody using recommended dilution ranges (1:100-1:300)

• Inconsistent Results Between Experiments:

  • Problem: Variable phosphorylation levels

  • Solution: Standardize cell handling procedures and lysis protocols to preserve phosphorylation status

  • Problem: Antibody degradation

  • Solution: Store antibody according to manufacturer recommendations (-20°C, avoid repeated freeze-thaw cycles)

• Cross-Reactivity Issues:

  • Problem: Detection of non-specific bands

  • Solution: Include a blocking peptide control and optimize antibody concentration

  • Problem: Signal in unexpected species

  • Solution: Verify sequence homology around the S355 site in your species of interest

How can researchers validate the specificity of Phospho-ANAPC1 (S355) antibody for their particular experimental system?

A comprehensive validation approach includes:

• Phosphatase Treatment Control:

  • Treat duplicate samples with lambda phosphatase before Western blotting

  • Loss of signal confirms phospho-specificity

• Peptide Competition Assay:

  • Pre-incubate antibody with immunizing phospho-peptide before application

  • Reduction or elimination of signal indicates specificity for the phospho-epitope

• Genetic Validation:

  • Generate S355A mutant (non-phosphorylatable) constructs of ANAPC1

  • Express in cells and confirm loss of signal

  • For endogenous validation, consider CRISPR-Cas9 knock-in approaches

• Correlation with Cell Cycle Stages:

  • Analyze synchronized cell populations at different cell cycle phases

  • Confirm expected increase in S355 phosphorylation during mitosis

• Mass Spectrometry Validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm enrichment of phosphorylated S355-containing peptides

• Cross-Antibody Validation:

  • Compare results from multiple phospho-ANAPC1 (S355) antibodies from different manufacturers

  • Consistent patterns increase confidence in specificity

What are the best practices for storage and handling of phospho-specific antibodies to maintain optimal activity?

To preserve antibody performance:

• Storage Conditions:

  • Store at -20°C or -80°C as recommended by the manufacturer

  • For frequently used antibodies, prepare small working aliquots to avoid repeated freeze-thaw cycles

  • Some formulations can be stored at 4°C for up to one month for short-term use

• Buffer Composition:

  • Most phospho-specific antibodies are supplied in buffers containing:

    • 50% glycerol (cryoprotectant)

    • 0.5% BSA (stabilizer)

    • 0.02% sodium azide (preservative)

    • PBS or potassium phosphate buffer

  • If planning conjugation, special formulations without BSA may be requested

• Handling Procedures:

  • Thaw antibodies on ice

  • Centrifuge briefly before opening to collect contents at the bottom of the tube

  • Avoid contamination by using sterile pipette tips

  • Return to storage promptly after use

• Special Considerations:

  • For immunoprecipitation applications, avoid buffer components that might interfere with binding (e.g., sodium azide)

  • For conjugation chemistry, request carrier-free formulations or perform buffer exchange

  • BSA-free formulations may be available upon request for specific applications

Following these practices will help maintain antibody performance and extend shelf-life beyond the typical one-year guarantee provided by manufacturers .

How can phospho-ANAPC1 detection be integrated into single-cell analysis workflows?

Emerging approaches for single-cell level detection include:

• Single-Cell Western Blotting:

  • Microfluidic platforms allow Western blot analysis of individual cells

  • Phospho-ANAPC1 detection could reveal cell-to-cell variation in APC/C regulation

• Mass Cytometry (CyTOF):

  • Conjugate phospho-ANAPC1 antibodies to metal isotopes

  • Combine with other cell cycle markers for high-dimensional analysis

  • Enables visualization of ANAPC1 phosphorylation heterogeneity in complex populations

• Imaging Mass Cytometry:

  • Apply metal-conjugated antibodies to tissue sections

  • Provides spatial information about phospho-ANAPC1 in the tissue microenvironment

  • Can reveal relationships between cell cycle state and tissue architecture

• Single-Cell Phosphoproteomics:

  • Use phospho-ANAPC1 antibodies for targeted enrichment

  • Combine with single-cell MS approaches to profile phosphorylation networks

• Live-Cell Imaging:

  • Develop phospho-specific intracellular sensors

  • Monitor dynamic changes in ANAPC1 phosphorylation during cell cycle progression

These approaches promise to reveal how ANAPC1 phosphorylation heterogeneity contributes to cell fate decisions and responses to therapeutic interventions.

What is known about ANAPC1 phosphorylation in the context of cancer and other diseases?

Current research has identified several disease associations:

• Cancer Connections:

  • ANAPC1 has been implicated in myeloma pathogenesis

  • Phospho-ANAPC1 shows positive staining in pancreatic carcinoma cells

  • Dysregulation of the APC/C complex is linked to chromosomal instability in various cancers

• Neurodegenerative Disorders:

  • The APC/C complex has roles in neuronal function beyond cell cycle regulation

  • ANAPC1 phosphorylation status in non-dividing neurons remains to be characterized

  • Potential involvement in neurodegeneration through protein degradation pathways

• Development and Differentiation:

  • APC/C regulates important developmental transitions

  • ANAPC1 phosphorylation may serve as a marker for stem cell differentiation status

• Therapeutic Implications:

  • Targeting the phosphorylation of APC/C components represents a potential strategy for modulating mitotic progression

  • Monitoring phospho-ANAPC1 levels could indicate response to cell cycle-targeting therapies

Further research is needed to fully elucidate the role of ANAPC1 phosphorylation in disease pathogenesis and its potential as a biomarker or therapeutic target.

How do new technologies like protein phase separation impact our understanding of ANAPC1 phosphorylation?

Recent advances in biophysical concepts offer new perspectives:

• Biomolecular Condensates:

  • Phosphorylation can drive phase separation of proteins into membraneless organelles

  • ANAPC1 phosphorylation might contribute to the formation of mitotic regulatory condensates

  • This could explain the observed nuclear and cytoplasmic localization patterns

• Super-Resolution Microscopy:

  • New imaging technologies can visualize phospho-ANAPC1 localization with unprecedented detail

  • May reveal specific subcellular compartments where phosphorylated ANAPC1 concentrates

• Cryo-Electron Microscopy:

  • Structural studies can determine how phosphorylation alters ANAPC1 conformation

  • Recent advances in Cryo-EM have revealed detailed structures of the APC/C complex

• Proximity Labeling Approaches:

  • BioID or APEX2 fusions to ANAPC1 can identify proteins that interact specifically with the phosphorylated form

  • These methods work in living cells and capture transient interactions

• Optogenetic Control:

  • Light-inducible phosphorylation systems could be developed to temporally control ANAPC1 modification

  • Would allow precise determination of the functional consequences of S355 phosphorylation